ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Verve Therapeutics Inc

Verve Therapeutics Inc (VERV)

7.095
0.205
(2.98%)
Closed July 23 4:00PM
7.2664
0.0864
(1.20%)
After Hours: 6:02PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
7.2664
Bid
7.09
Ask
7.10
Volume
560,490
6.76 Day's Range 7.185
4.585 52 Week Range 21.04
Market Cap
Previous Close
6.89
Open
6.99
Last Trade
30
@
6.84
Last Trade Time
Financial Volume
$ 3,893,765
VWAP
6.9471
Average Volume (3m)
1,425,024
Shares Outstanding
83,965,493
Dividend Yield
-
PE Ratio
-2.98
Earnings Per Share (EPS)
-2.38
Revenue
11.76M
Net Profit
-200.07M

About Verve Therapeutics Inc

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Verve Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VERV. The last closing price for Verve Therapeutics was $6.89. Over the last year, Verve Therapeutics shares have traded in a share price range of $ 4.585 to $ 21.04.

Verve Therapeutics currently has 83,965,493 shares outstanding. The market capitalization of Verve Therapeutics is $578.52 million. Verve Therapeutics has a price to earnings ratio (PE ratio) of -2.98.

VERV Latest News

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...

Verve Therapeutics Announces Leadership Update

Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE...

Verve Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.51647.650370370376.757.966.613574117.2868005CS
41.956436.84369114885.317.964.58513694045.96178629CS
121.016416.26246.257.964.58514250245.76222327CS
26-4.7536-39.547420965112.0219.344.58513293668.70756427CS
52-13.5436-65.082172032720.8121.044.585127147610.63359807CS
156-46.2736-86.428091146853.54784.58591126519.44909024CS
260-22.7336-75.778666666730784.58590435520.0574936CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
151.42M
CMAXCareMax Inc
$ 5.7101
(261.40%)
100.56M
NUKKNukkleus Inc
$ 0.5415
(69.22%)
24.87M
SNOASonoma Pharmaceuticals Inc
$ 0.423
(37.34%)
4.57M
LPSNLivePerson Inc
$ 1.2999
(31.30%)
8.57M
LGCBLinkage Global Inc
$ 3.6601
(-29.82%)
168k
CGBSCrown LNG Holdings Ltd
$ 0.9997
(-29.10%)
3.39M
SPECSpectaire Holdings Inc
$ 0.3962
(-24.53%)
1.87M
GSUNGolden Sun Health Technology Group Ltd
$ 5.13
(-23.66%)
158.79k
PSNLPersonalis Inc
$ 2.9808
(-22.58%)
3.11M
NVDANVIDIA Corporation
$ 123.45
(4.68%)
221.22M
SQQQProShares UltraPro Short QQQ
$ 8.08
(-4.49%)
176.65M
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
151.42M
SERVServe Robotics Inc
$ 8.7192
(15.49%)
148.59M
NCPLNetcapital Inc
$ 0.1105
(6.25%)
121.97M

VERV Discussion

View Posts
Monksdream Monksdream 3 weeks ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 4 weeks ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
VERV more new lows up ahead
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
VERV new 52 lo
πŸ‘οΈ0
Firestorm22 Firestorm22 4 months ago
uh oh
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
VERV over $10
πŸ‘οΈ0
fink fink 5 months ago
Looking for an entry now
πŸ‘οΈ0
Terpi Terpi 8 months ago
Could see another nice move here is the 50 day holds into close.
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
VERV morning rally
πŸ‘οΈ0
TheFinalCD TheFinalCD 1 year ago
https://cathiesark.com/
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
VERV IS A GREAT $$$$$ OPPORTUNITY.
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock